RHHBY Roche Holding AG

Sentiment & Price 2 ideas • 2 voices • 2 sources ▼
Sentiment Gauge
0
Bull
0
Bear
0
Watch
Bull 50% Bear 50%
Price & Sentiment
Loading chart...
Recent News Top Views ▼
No recent news for RHHBY
No theses available
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:53
Mar 19
A May MD Biotech investor
The author correctly predicted the failure of Roche's MANATEE study, highlighting a potential shift in the competitive landscape for myostatin drugs.
RHHBY
10:50
Mar 06
Chloe Whiteaker Bloomberg Equities Reporter Bloomberg Markets
Roche's experimental obesity shot "disappointed investors" with weight loss comparable to a placebo. The obesity market is a duopoly (Novo/Lilly). Roche failing to clear the bar removes a potential competitor but severely damages Roche's growth narrative in this high-value sector. SHORT/AVOID Roche as it falls behind in the GLP-1 race. Roche's legacy portfolio outperforms or they acquire a new biotech asset.
RHHBY

About RHHBY Analyst Coverage

Buzzberg tracks RHHBY (Roche Holding AG) across 2 sources. 0 bullish vs 2 bearish calls from 2 analysts. Sentiment: mixed to bearish. 2 total trade ideas tracked.